MedTrace Logo

Mesylate Apatinib for Stage â…£ STS After Failure of Chemotherapy

NCT03121846 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2017-05-22

No results posted yet for this study

Summary

This is a Prospective, Open-label, Single-Arm, Multi-center phase II clinical trial evaluating the efficacy and safety of Apatinib for Chemotherapy Failure â…£ Stage Soft Tissue Sarcoma.

Conditions

  • Soft Tissue Sarcoma, Adult, Stage II

Interventions

DRUG

Apatinib

Apatinib 500 mg is administered orally daily, until disease progression or untolerable toxicity.

Sponsors & Collaborators

  • Zhejiang Cancer Hospital

    collaborator OTHER

  • Gansu Cancer Hospital

    collaborator OTHER

  • Liaoning Cancer Hospital & Institute

    collaborator OTHER

  • Fudan University

    collaborator OTHER

  • Tianjin Medical University Cancer Institute and Hospital

    lead OTHER

Principal Investigators

  • Jilong Yang, M.D., Ph.D. · Tianjin Medical University Cancer Institute and Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-05-01
Primary Completion
2018-11-01
Completion
2019-05-01

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03121846 on ClinicalTrials.gov